[Last updated on 20 May 2022]
The research-based pharmaceutical industry in Europe stands in solidarity with the people of Ukraine. We condemn the invasion of their country and express our sorrow at the suffering it has caused. As an industry dedicated to saving and improving lives, we stand for peace.
Our first priority is to ensure that medicines reach the patients that need them in Ukraine, in the neighbouring EU Member States, in Russia and in other countries where access to medicines may be negatively impacted. We call on all parties to facilitate the safe passage of medicines and vaccines to those in need.
As a health-based industry and part of the wider EU healthcare community, we will work together to address the health needs of all those affected by this war, in Ukraine and in neighbouring countries as part of the wider humanitarian relief effort.
Our Member Companies and Associations are offering humanitarian support both in Ukraine and for the emerging refugee crisis in neighbouring EU Member States. To date this includes in over 5 million doses of essential medicines and more than €62 million in financial support to NGOs.
AbbVie's response to the Ukraine crisis
Our thoughts are with the people of Ukraine and those affected across the region. As a global biopharmaceutical company, we have a responsibility to patients who depend on our medicines. We are committed to ensuring our patients in Ukraine, Russia and throughout the region continue to have access to our essential and life-saving medicines.
AbbVie's presence in Ukraine and throughout the region
Our priority is to ensure the safety of our colleagues and help patients get the medicines they need.
As the tragic events continue to unfold in Ukraine, AbbVie has temporarily suspended operations for all our aesthetics products in Russia.
We do not have any manufacturing plants in the region. Importantly, we continue to monitor the safety of our employees in Ukraine and the surrounding region.
Status of Clinical Trials
AbbVie is doing everything possible to minimize disruption to the treatment and care of our patients and clinical trial participants. We have paused the start of new clinical studies and the screening and enrollment of clinical trial participants in ongoing studies in Ukraine and Russia. We are committed to ensuring our clinical trial participants have access to the investigational medicines they need.
Humanitarian / Philanthropic response
Our philanthropic focus is on humanitarian, employee, and donation support.
- Donating a total of $1 million to nonprofit partners for medical care and supplies for Ukraine and Ukrainian refugees.
- Donating essential medicines to the Ukrainian government and our disaster relief partners.
- Providing relief and additional financial support as needed to Ukrainian employees and their immediate families.
- Doubling the AbbVie Foundation's employee donation match for select disaster relief partners with active humanitarian relief efforts in Ukraine and surrounding countries.
As this situation evolves, we will continue working with our nonprofit partners and employees to support relief efforts as we hope for a peaceful resolution.
We continue to provide urgent humanitarian support in Ukraine and neighbouring countries. To date, we have committed over $7 million to response efforts, including donations of:
- Twenty-four pallets of medicines, worth $3 million, to our humanitarian relief partner Direct Relief, which is working directly with the Ukrainian Ministry of Health.
- $2 million to support relief agencies working in Ukraine, Poland and surrounding areas with a focus on providing healthcare and humanitarian assistance to those affected by the conflict. Funding is being provided to Project HOPE, working with and through the World Health Organization, and International Medical Corps.
- Medicines via The Red Cross affiliates in neighbouring countries to respond to the unfolding refugee crisis.
- >$1 million to UNICEF and The Red Cross, including over $500k of employee donations, which AstraZeneca is matching.
We continue to be deeply concerned by the tragic war in Ukraine, the devastating losses of civilians and the suffering of the entire Ukrainian population.
This led us to take several further and immediate actions:
In addition to the original donation of BERLIN-CHEMIE, a further donation of 200,000 euros directly to the Red Cross was carried out at Menarini Group level, complemented by 60,000 euros donated worldwide by its employees (matched equally by the Group), totalling the economic donations at 420,000 euros. Including the continuous medicine donations, our total contribution dedicated to the Ukrainian people is well over 1 million euros by now.
In Russia, we have stopped all advertising spending, ceased all new investments and implemented a headcount freeze. International sanctions exclude pharmaceuticals and we continue to supply medicines to Russia focused on patients who depend upon them.
We stand with the Ukrainian people and hope for a peaceful resolution as soon as possible.
Boehringer Ingelheim condemns the military aggression against Ukraine.
“On behalf of the Board of Managing Directors, I would like to express our feelings of sorrow and consternation over the start of a war in the middle of Europe. This affects people across the region, where families have members on both sides of the border, and where sons and daughters are called to duty in a war that only brings suffering and pain”, says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “War can never be accepted as the means of resolving conflicts.”
It was in February 1992 that we established our presence in Ukraine and Russia, which has grown to a total of nearly 800 employees today. "During these 30 years, we have achieved many milestones together in the interest of health, for the benefit of patients, and in the interest of life. Our Ukrainian as well as Russian colleagues have become integral members of the Boehringer Ingelheim family,” Hubertus von Baumbach continued. "Our thoughts are with them, as well as the many people who simply want to live in peace. On behalf of my colleagues, my deepest sympathies are with them all.”
“We have decided to make a donation of EUR 2.5 million* to charitable organizations providing humanitarian support to Ukraine and its citizens.”
Many colleagues are working to ensure the safety and well-being of our employees and their families in any way possible. We are in close contact with our Ukrainian colleagues. At the same time, we are seeking to limit the impact of the conflict on the supply of medicines to patients for humanitarian reasons across both countries. “We would like to thank all who have worked tirelessly during the past days to provide help wherever help can be provided.” Hubertus von Baumbach promises: “We will do everything to help our impacted colleagues, their families and communities.”
We realize that the war will have a long-term impact. We will therefore donate 12 monthly payments of each EUR 1 million to the Polish and German Red Cross organizations, from this month (March).
* The donation will be distributed to the following charitable organizations:
- EUR 750k to International Committee of the Red Cross (via German Red Cross - DRK)
- EUR 750k to Aktionsbündnis Katastrophenhilfe
- EUR 500k to Aktion Deutschland Hilft
- EUR 500k to UNO-Flüchtlingshilfe
Read more here
Multiple Daiichi Sankyo group companies are likewise donating, by contributing to their local charities and leveraging gift matching programs, adding to our overall support for those affected by this conflict. We are also thankful to our many employees who are helping privately, including by hosting refugees in their homes.
We are working with our partners across the globe to ensure, as much as possible, that patients retain access to our medicines and our clinical trials worldwide.
Ipsen is providing humanitarian relief to the people of Ukraine via a donation of €1.5 million, split between two humanitarian organizations.
- Tulipe collects donations from health companies to respond to the emergency needs of populations in distress during acute health crises, natural disasters and conflicts via its partners in the field.
- The Red Cross in France an independent charity working alongside governments and public authorities which undertakes neutral and impartial humanitarian action.
· Donating $5 million to support the work of the International Rescue Committee (IRC) and International Federation Red Cross and Red Crescent to provide humanitarian support for refugees in the border countries.
· Providing product donations including hygiene kits, health packets and medical supplies.
· Launching an unlimited matching program for our global employees with Global Giving Ukraine Crisis Relief Fund.
· Continuing to work with our longstanding partners in global health—International Health Partners (IHP, UK), Americares (US), Direct Relief (US), IFRC, Save the Children and UNICEF—to support those in the region by providing them access to our supply chain network to strengthen their reach and capabilities.
Almirall stands in solidarity with everyone who is suffering first-hand the consequences of the conflict and humanitarian crisis in Ukraine.
As a company we are also committed to helping the humanitarian relief efforts and we have launched the giving campaign “Together with Ukraine” that is matching employee donations globally. All funds raised will be donated to the Spanish Red Cross (Cruz Roja Española), who will support the Ukrainian Red Cross response as well as regional Red Cross efforts in neighbouring countries.
Almirall is also accelerating donations of relevant medicines to NGOs operating in Ukraine and bordering countries. In the next few days, we will send a total of more than 150,000 units of relevant medicines.
As a global biopharmaceutical company, we uphold respect for fundamental human rights around the world as part of our purpose to improve people’s lives.
Our thoughts are with the people of Ukraine, and we hope for a swift and peaceful resolution to the situation.
Our priority is on the safety of Astellas Ukraine employees and their families. Also, we are ensuring on-going partnership and connectivity with suppliers, distributors and key stakeholders to do our best efforts for continuous supply for patients.
We have taken steps to support the people in Ukraine. We are donating 10 million yen to UNICEF to support their humanitarian effort. We are also looking at other philanthropic options including essential drug donation and fund raising.
At Astellas, we are at the forefront of healthcare change to turn innovative science into VALUE for patients. We remain committed to our mission in all the countries where we operate.
We stand by the people of Ukraine who can fully count on our solidarity and support, and will do everything in our power to live up to our responsibility to reduce the suffering caused by this terrible war.
Bayer announced a € 3 million disaster relief fund to strengthen emergency measures in response to the invasion of Ukraine. The support fund is benefiting international and local humanitarian aid organizations engaging in Ukraine and Eastern European neighboring states. The fund includes the company’s initial humanitarian response released only one day after the first attacks, making 300,000 Euros available for immediate aid by the German Red Cross and local organizations. In particular, we delivered financial support to the “Kharkiv with You” Charitable Foundation in the amount of € 50 thousand for the essential hygiene products and food for residents of Kharkiv and nearby towns.
Additional product donations for the population of Ukraine amount to € 2.4 million in numerous cases. In particular, at the request of the Ukrainian Ministry of Health and the National Cancer Institute, Bayer donated antibiotics to help up to 30,000 Ukrainian patients, as well as medicines in the areas of anti-inflammatory, cardiovascular, antihistamine, cancer, diagnostic, and skin diseases treatment.
Our employees worldwide also responded generously – donating more than € 1 million through the Red Cross relief campaign. Additionally, Bayer colleagues have set up a platform where employees offer housing and support to colleagues from Ukraine and their families who may need temporary shelter.
Also, as the company working in the field of agriculture, Bayer strives to support protecting food supply chains from further disruption. Our seeds and agricultural inputs stand ready for the planting season for farmers in Ukraine. In addition to this, Bayer has donated more than 40,000 bags of seeds to grow food on nearly 30,000 hectares to support 1,250 small Ukrainian farmers
Bristol Myers Squibb and the Bristol Myers Squibb Foundation are each actively contributing to relief efforts in Ukraine, donating more than $1 million total to date.
The Company has provided donations to a number of organizations coordinating relief efforts; this includes activities organized by the World Institute on Disability and the ECO-ASCO special network, working with WHO Europe to pool information to aid the coordination of transfer and care for Ukrainian cancer patients.
The Bristol Myers Squibb Foundation has provided donations to organizations, including Americares, Direct Relief, International Rescue Committee, and Save the Children.
The Foundation is also matching contributions by our employees globally to organizations providing relief to Ukraine.
Aligned with Our Promise to protect human health, CSL is supporting multiple humanitarian relief efforts in the region. We are working with aid organizations, including the World Health Organization (WHO), the European Health Emergency preparedness and Response Authority (HERA), the EU Civil Protection Mechanism and the Red Cross to provide our life-saving medicines to those impacted by the invasion. We have also been coordinating our local relief efforts with international organizations, including Doctors Without Borders and UNICEF.
By providing our medicines through humanitarian, intergovernmental and EU-coordinated efforts, we will help refugees and those who remain in Ukraine access essential therapies.
In addition to providing our life-saving medicines, CSL has pledged to match monetary donations from our eligible employees around the world to support urgent relief efforts, including a program that enables eligible employees to donate plasma at CSL Plasma collection centers and then direct the payment to the Red Cross.
Together, our product and monetary contributions will continue to support relief efforts both within Ukraine and in neighboring countries.
While we continue to keep the Ukrainian people, and those in the surrounding regions, in our thoughts as we hope for a peaceful resolution, we also understand there are many people in Russia who rely on our life-saving therapies. CSL will continue to support those living with rare and serious diseases in Russia and supply products which are critical for patients. As the invasion persists, CSL will not conduct any promotional activities and will not start new clinical trials in Russia until further notice.
Under its hhc philosophy to increase the benefits that medicines bring to patients and their families, the Eisai Group, as an international pharmaceutical company, strives to contribute to the health and well-being of all people, wherever they may be.
To further this mission, we are working with various partners including the International League Against Epilepsy to make our medicines available to those patients who have been displaced by the war in Ukraine and who are in desperate need of medication. In addition, as humanitarian support to those who have been severely affected in Ukraine and those who have been evacuated to the surrounding countries, the Eisai Group has donated approximately 16 million yen to the Japanese Red Cross Society, the international non-governmental organization Association for Aid and Relief (AAR), Japan and other organizations.
Alongside the global community, we share deep concern about the tragic events happening in Ukraine. We are taking actions guided by our purpose, and as a company dedicated to health and care for people and patients.
Our first priority is the safety, security and wellbeing of GSK people, wherever they are located. After this, our focus is to make sure our products reach the people who need them, including supporting humanitarian efforts in Ukraine and surrounding countries.
We condemn the fighting and the harm and suffering it’s causing to people in Ukraine and beyond. The actions taking place are in violent contradiction to our purpose, and unshakeable belief that all people should be treated with dignity, respect and humanity.
For full information on GSK’s humanitarian support and GSK in Russia, please visit GSK.com [Our response to the situation in Ukraine | GSK].
Lilly is donating $7.5 million of insulin to Project Hope, a U.S. non-profit organization that empowers health care workers facing the world’s greatest health crises to build resilient communities and a healthier, more equitable world. Project Hope is currently on the ground in Ukraine and is actively shipping essential medicines and medical supplies to assist Ukrainians.
Support for Relief Organizations
The Lilly Foundation is also making two equal monetary contributions totalling $500,000 to Direct Relief and to Americares to support their respective relief efforts in the region. Americares is currently working to deliver aid for families facing crisis in Ukraine. They are collaborating closely with the World Health Organization, regional health authorities, and international, national and local response organizations in Ukraine and neighbouring countries.
The Lilly Foundation will also match eligible Lilly employee donations up to an additional $500,000. We hope for an immediate end to the hostilities and a peaceful resolution to this crisis as soon as possible.
More information is available here Lilly Ukraine Support | Eli Lilly and Company
*The Eli Lilly and Company Foundation, Inc. is a separate, tax-exempt organization.
The French pharmaceutical industries support the Ukrainian population by sending medical products on territories at war through their association Tulipe.
Thanks to the donation of the volunteer French pharmaceutical firms, the association managed to route to Ukraine and Poland more than 50 tons of medical products (war medicine material and general medical products for refugees) since the beginning of the armed conflict. These donations are organized in coordination with the Crisis and Support Center (CDCS) of the Ministry for Europe and Foreign Affairs and various NGOs.
As the conflict continues, more donations are on the way for the coming days and weeks, in partnership with humanitarian organizations located in the field. (May 2022)
LEO Pharma stands united with the people of Ukraine and with the international community in condemning the invasion.
As of March 22nd 2022, LEO Pharma has decided to donate close to 740,000 packs and 420,000 vials of antibiotics and anticoagulants via International Health Partners. These medicines are relevant for treating wounds, infections and saving lives to support people in vulnerable communities in Ukraine.
The products have an estimated value of EUR +1.8 million and is a donation on top of the DKK 1 million (EUR 135,000) donated to the Danish Red Cross.
- To support humanitarian aid in Ukraine, Merck has donated two million euros to the German Red Cross. One million euros of this amount were contributed by the Merck Family.
- In addition, we have created a donation platform to enable employees at Merck to also contribute. Donations made here will be matched by the company. Our employees have already donated close to 550,000 Euros (Status: March 30)
- Merck colleagues across the company, particularly in countries bordering on Ukraine such as Poland, are volunteering to support in any way they can: Welcoming Ukrainian refugees to their homes, organizing the transportation of care packages with food and hygiene products and connecting on our intranet as well as locally to share information about ways to help and donate.
- Our employees in Darmstadt and Gernsheim in Germany donated seven metric tons of urgently needed relief supplies such as non-perishable food, hygiene items, sleeping bags, bedding and blankets, strollers and toys. In addition, Merck donated eight metric tons of non-perishable food and first-aid kits. All relief items went to the Polish NGO “Centrum Sektor 3”, which is providing humanitarian aid to Ukrainian refugees who have arrived in Wroclaw since the beginning of the war.
- In response to an open request from the Ukrainian government, we have supplied 23,000 liters of disinfectants manufactured by Merck for use by their civilian population. Distribution is being managed by the Hessian government.
Novartis condemns the war in Ukraine. This unprovoked act of violence harms innocent people and defies our mission to improve human health globally.
As a medicines company, in the last few days, we have delivered more than 600 thousand packs of antibiotics, painkillers, cardio-vascular, and oncology treatments to maintain supply to those who rely on these drugs in Ukraine and in the border areas where people are seeking refuge.
Novartis has also made an initial USD 3 million donation to charities supporting refugees and displaced people in Ukraine and bordering countries. We are continuing to support our employees and their families in Ukraine, and those who have left the country. Our thoughts are with the citizens of Ukraine, Novartis will continue to contribute to the humanitarian efforts in and for the people of the country.
We remain committed to providing access to medicines to patients in every country where we operate. At the same time, we are careful to comply with the international sanctions imposed upon Russia.
We have implemented a package of measures that include suspending capital investments, media advertising, and other promotional activities in Russia. In addition to that, while we remain committed to provide access to our medicine in Russia, we responsibly pause the initiation of new clinical trials and the enrollment of new study participants in existing trials. These measures will be kept under review.
We are hopeful that the war in Ukraine will soon reach a peaceful resolution.
As the humanitarian crisis deepens in Ukraine, all at Otsuka watch with great sadness and a feeling of helplessness. The impact on the people in Ukraine and those fleeing their homes is unimaginable and we hope that our donation of €100,000 to the British Red Cross will contribute to providing a degree of safety and security to those affected by this humanitarian crisis. We continue to monitor the situation and respond with support where we can.
We are working diligently to support the country and people of Ukraine with medical products in accordance with Roche’s overall mission. As a first initiative, we donated a critical antibiotic and specialised medicines for the treatment of anaemia, a wide variety of bacterial infections, influenza, rheumatoid arthritis, SMA and various cancers as well as rheumatoid arthritis and COVID-19. We also donated reagents and consumables for automatic testing of blood donations and units for diabetes management.
We remain in contact with multiple global and local partners as well as charities to understand how it can best continue to support the people of Ukraine with additional medical supplies.
Ensuring critical medicines and diagnostics reach the people who need them is extremely important to us and we are making every effort to ensure continued supply within the scope of the available possibilities.
We are working with local distributors in Ukraine, and have set up a remote support system for laboratories, through our Diagnostics Customer Support Center in Poland.
We have established a global hotline number and invite patients, caregivers, physicians, clinical trial participants, investigators or coordinators, and healthcare providers to call. Our team will do its best to provide everyone who is in need with the appropriate information and support. The hotline is available in multilingual and can be reached on the following number: +36 146 182 58.
The situation is evolving quickly and further details will be shared when available.
Find more information about our donations here:
Our commitment to patients, regardless of where they live, and to our people is unwavering and is even more important in times of crisis. We are making every effort to protect our colleagues in Ukraine and to continue to supply patients in Ukraine and in the region with much needed treatments.
We are supporting the global humanitarian efforts by contributing JPY 300 million (approx. $2.6 million USD) to The International Federation of Red Cross and Red Crescent Societies, which is actively providing urgent local humanitarian support to people displaced and impacted by the conflict. We are also donating medicines to hospitals working to provide care around the clock to patients in need, and will continue to evaluate ways to provide additional support services for patients and the treatment community. Our colleagues around the world are helping those in need in Ukraine by contributing with their personal donations to several local and global non-governmental organizations.
As the conflict and humanitarian crisis in Ukraine continues, we are announcing an update to our company position in Russia.
Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to our employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrollment of new patients in ongoing clinical trials.
Our focus only on essential activities is consistent with our values and ethical responsibility to our patients in Ukraine, Russia and the region who depend on our treatments. Notwithstanding, we are adhering to all international sanctions imposed on Russia.
We will be increasing our humanitarian relief efforts, including monetary and medicine donations to benefit people affected by the conflict in Ukraine, and we will continue to assess new ways to provide support as we look to meet the needs of patients across the region.
Takeda will continue to monitor the situation closely and take appropriate actions grounded in our values.
In these difficult times, UCB is guided by our purpose of creating value for patients, now and in the future and our focus on contributing to a more inclusive and sustainable world. That’s why we are driven to limit the impact of this unfortunate war on our employees, patients and their respective communities.
We are fully focused on supporting the small group of UCB employees living in Ukraine, as well as their families, and we have foreseen emergency support for our colleagues.
We feel responsible to bring medicines to people living in Ukraine and Russia no matter how difficult the circumstances. We will do everything within our power to ensure patients have access to their medicines. This is extremely difficult because of disrupted supply chains. In spite of this, we continue to investigate short and longer-term solutions to ensure availability of our medicines in the region. We have a cooperation with NGOs such as Tulipe who are delivering drug donations to patients in the war zone. So far, we have donated more than 1,6 million doses of anti-epileptics and 35,000 daily doses of antihistamines.
To support humanitarian efforts, UCB has donated EUR 300,000 to the German International Rescue Committee and the Belgian International Red Cross. We are also examining how we can support the communities in the region and those who have fled to safer places in the long-term, through our UCB Community Health Fund.
UCB colleagues around the world are showing solidarity, helping in refugee centers, making personal donations to charities, setting up collection of essential goods at UCB sites, driving to the Ukrainian border to pick up relatives or friends and hosting Ukrainian colleagues and refugees in their houses or those of other colleagues. These are only a few examples. To facilitate this much-needed movement of solidarity, we have developed an employee volunteering initiative to enable our colleagues in Europe to lend a helping hand to this enormous refugee crisis.
UCB in Russia
UCB is still bringing medicines to patients in Russia but we have reviewed the way in which we conduct our business there. Profits generated in Russia will be donated to the German International Rescue Committee and the Belgian International Red Cross to help the people of Ukraine. We have already stopped enrolling new patients and are not starting up any new sites or clinical trials in Russia. We are no longer undertaking marketing activities and are exploring other steps we can take to support the sanctions.
Our priority has been and will continue to be to take care of our colleagues and patients both in Ukraine and Russia that are innocent people in the midst of war.
MSD has a more than 130-year legacy of saving and improving lives around the world, and we remain committed to doing so. We are saddened by the invasion of Ukraine and stand united with the Ukrainian people who face a humanitarian crisis. MSD’s hope is for an urgent resolution, and our paramount concerns are the safety and well-being of our employees and ensuring our patients and customers have continued access to our medicines and vaccines.
For humanitarian reasons, MSD has a responsibility to continue supplying essential medicines and vaccines in Russia. Any profits resulting from these sales will be donated to humanitarian causes. We will maintain scientific exchange of information with stakeholders in critical therapeutic areas. However, the company will not make further investments in Russia. This includes stopping all promotional activities, capital investments and business development initiatives. Additionally, screening and enrollment in ongoing clinical trials, and planning for new studies in Russia have been suspended. We are continuing to treat patients already enrolled in existing clinical trials and collect data from these studies underway, and we are working hard to ensure no patient is left behind. MSD does not have research or manufacturing facilities in Russia and is operating in compliance with all international sanctions while working to ensure continued access to essential medicines and vaccines. During this time of tragedy, MSD’s commitment to helping the people affected is unwavering. We are using our resources to help alleviate the human suffering in Ukraine. MSD is taking various actions to address the humanitarian crisis, which include the:
- Delivery of molnupiravir to Ukraine through a supply and purchase agreement we have with the government.
- Donation of molnupiravir to Direct Relief for distribution to refugees. We are preparing to donate additional courses specifically for people affected by the invasion of Ukraine.
- Donation of product, including PROVENTIL, an inhaler used in patients with asthma and TIENAM IV (marketed as PRIMAXIN in the U.S.), an antibiotic used to treat infections in hospitalized patients and KEYTRUDA for existing patients in need. We are actively assessing needs for additional products.
- Commitment of $1 million USD to NGOs, including $300,000 USD to the American Red Cross, delivering urgent assistance to those affected in the region.
- Utilization of our donation program for U.S. and Puerto Rico employees to donate to Ukraine relief efforts. Contributions will be matched 100% by the Company. Employees outside of the U.S. can receive a company match toward their donation to the Red Cross and to Direct Relief, and the contribution will be matched 100% by the company.
- Donation of vaccines from MSD Animal Health to farmers in Ukraine to support the continued raising of livestock and food production.
As of April 13, our total cash and product donations amount to more than $95 million USD.
MSD will continue to monitor this tragedy and update its response as this crisis unfolds. The focus now remains on supporting the well-being of our employees and doing what we can to ensure access to our medicines and vaccines, and further using our resources to alleviate the unimaginable human suffering in Ukraine.
With normal supply chains disrupted, we are in dialogue with several international humanitarian organisations to provide relief and have donated medicines and supplies to the Ukrainian Ministry of Health.
We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.
Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created. Deeply concerned by the human suffering we all are witnessing during the ongoing crisis in Ukraine, Pfizer is committed to contributing to ongoing humanitarian efforts that support the safety, health and wellbeing of people affected by these tragic events.
Through The Pfizer Foundation*, we have provided US $2 million in humanitarian grant funding to the following organizations working in Ukraine and surrounding countries:
- American Red Cross to support emergency teams in Ukraine and surrounding countries who are working to repair vital infrastructure, support health facilities with medicines and equipment, and support families with food and hygiene resources. Funds donated through the American Red Cross will support the Ukrainian Red Cross response, as well as regional Red Cross efforts in surrounding countries to support immediate needs of affected populations.
- International Medical Corps (IMC) to support essential emergency and primary health services, mental health and psychosocial support services, and protection and gender-based violence services, which are critical for conflict-affected communities. COVID-19 awareness and prevention services will be incorporated into these efforts to help keep displaced people safe from the pandemic.
- International Rescue Committee (IRC) to support their efforts in bordering countries to mobilize resources and connect with partners to help provide life-saving support to people forced to flee their homes.
- The UN Refugee Agency (UNHCR) to support emergency relief priorities in Ukraine and immediate needs of displaced populations in surrounding countries now hosting Ukraine refugees. UNHCR is the leading UN agency coordinating all inter-agency regional efforts across UN agencies, NGOs and other relevant partners to maximize and effectively coordinate refugee response efforts.
We have launched the Ukraine Humanitarian Disaster Campaign to provide all eligible colleagues the opportunity to donate to key organizations helping those impacted by the conflict in Ukraine and neighboring countries. The Pfizer Foundation* is matching colleague financial donations made through this campaign to organizations including UNICEF, the International Rescue Committee, Save the Children, the American Red Cross, CARE, Nova Ukraine and Sunflower of Peace.
- As of March 11, 2022, thousands of colleagues from nearly 54 countries have donated nearly US $621,000.
- Including The Pfizer Foundation’s dollar-for-dollar match, the total donation is approaching US $1.25million
We have received detailed requests from the Ukrainian Ministry of Health through our NGO partners for medicines and vaccines and have responded with donations both from our existing supply in Ukraine and from the U.S. These donations — which include nearly 700,000 doses of lifesaving antibiotics, antifibrinolytics, and oncology medicines — are intended to help healthcare providers and relief workers treat patients in Ukraine and neighbouring countries.
Bearing in mind the exception of medicines from the international community’s sanctions on Russia, Pfizer has concluded that a voluntary pause in the flow of our medicines to Russia, including cancer and cardiovascular therapies, would cause significant suffering and potential loss of life, particularly among children and older people. Pfizer will donate all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.
*The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
The safety of our employees is our priority, and all of our teams are working tirelessly every day to support them and their families in every possible way.
Since the beginning of the war, we have worked to provide patients in Ukraine access to our vital treatments and to mitigate the impact of the situation on our ongoing clinical trials in the country.
Through our foundation, we’ve also donated EUR 5 million to the Red Cross for Ukraine and neighboring countries and to UNHCR, the UN Refugee Agency. This will support emergency access to necessities such as food, shelter, medicine, and security, and will help receive and assist refugees from Ukraine.
In coordination with authorities and our partners, we’re accelerating the donation of our essential medicines and vaccines to support both patients in Ukraine and Ukrainian refugees in neighboring countries. On 29th March, as our effort to support the European Commission’s ‘Stand Up For Ukraine' donation campaign, our foundation at Sanofi has donated nearly 300,000 vaccines to support diphtheria and tetanus vaccinations for Ukrainians. 200,000 shots will go to Ukraine, while another 70,000 will go to the Czech Republic, Slovakia and Moldova, which are hosting a significant number of Ukrainian refugees. (link to the European Commission Press Release)
In addition to our corporate donations, employee donations have also been organized across our affiliates.
We will continue to respond as the situation evolves.
Teva has shipped over 1.3 million packs of medicines, including antibiotics and other medicines listed on the WHO's list of essential medicines, as well as products for Ukrainian infants and children struggling with poor hygienic conditions.
If you want to learn more the full release is available here: https://bit.ly/3i4llGS
In light of the developing humanitarian crisis in Ukraine, our thoughts are with everyone affected - and in particular our patients, employees and their loved ones.
At Vifor Pharma, we are working hard to strengthen wider humanitarian efforts and have donated nearly 60,000 packages of iron therapies to help those in need in Ukraine. The use of the intravenous iron products in this emergency setting is hoped to improve surgical and medical outcomes in patients by optimal management of a patient’s additional transfusion needs during surgery as evidenced in the Patient Blood Management setting.
Vifor Pharma is a patient-centric company, and our greatest priority is to ensure that local healthcare organizations and patients receive the medicines they depend on in these uncertain times.